Dadun Dadun cabecera universidad cabecera biblioteca
   (New user)
Help  | Contact  |  Castellano English  
 

Dadun > Depósito Académico > CIMA (Centro de Investigación Médica Aplicada) > Área de Ciencias Cardiovasculares > Trombosis y hemostasia > DA - CIMA - Cardiovasculares - Trombosis y Hemostasia - Artículos de Revista >

The c.-1639G > A polymorphism of the VKORC1 gene is a major determinant of the response to acenocoumarol in anticoagulated patients
Authors: Montes, R. (Ramón)
Ruiz-de-Gaona, E. (Estefanía)
Martinez-Gonzalez, M.A. (Miguel Angel)
Alberca, I. (Ignacio)
Hermida, J. (José)
Keywords: Vitamin K
Drugs
Anticoagulation
Issue Date: 2006
Publisher: Blackwell Publishing
Publisher version: http://onlinelibrary.wiley.com/doi/10.1111/j.1365-2141.2006.06007.x/abstract
ISSN: 1365-2141
Citation: Montes R, Ruiz de Gaona E, Martinez-Gonzalez MA, Alberca I, Hermida J. The c.-1639G > A polymorphism of the VKORC1 gene is a major determinant of the response to acenocoumarol in anticoagulated patients. Br J Haematol 2006 Apr;133(2):183-187.
Abstract
Much of the variability in the sensitivity to warfarin in anticoagulated patients is associated with the c.-1639G > A polymorphism of the vitamin K-epoxide reductase (VKORC1) gene. However, its association with the acenocoumarol dose in patients under anticoagulant therapy has not been studied. The c.-1639G > A genotype of VKORC1 was determined in 113 patients on stable anticoagulation requiring low (n = 42), medium (n = 42) or high (n = 21) acenocoumarol doses. To evaluate the association between acenocoumarol requirements and the c.-1639G > A variant, multivariate logistic regression models were fitted, adjusting for age, gender, and the c.430C > T and c.1075A > C variants of cytochrome P450 2C9 (CYP2C9). A total of 90.5% of the patients in the low acenocoumarol dose group carried the A allele of VKORC1:c.-1639G > A. The A allele independently increased the odds of requiring a low acenocoumarol dose [odds ratio (OR) 9.4; 95% confidence interval (CI) 1.9-46.4; P = 0.006], especially when the homozygous form was present (OR 44.2; 95% CI 5.5-354.6; P < 0.001). The A allele was less frequent in the high dose group showing an inverse association with the requirement for high doses (OR 0.04; 95% CI 0.01-0.22; P < 0.001). The A allele of the c.-1639G > A polymorphism of VKORC1 is therefore associated with a low-dose requirement for acenocoumarol in patients receiving anticoagulant therapy.
Permanent link: http://hdl.handle.net/10171/21989
Appears in Collections:DA - Medicina - MPSP -Artículos de revista
DA - CIMA - Cardiovasculares - Trombosis y Hemostasia - Artículos de Revista

Files in This Item:
File:  BrJHaematol2006_133183.pdf
Description: 
Size:  81,73 kB
Format:  Adobe PDF
 View / Open 

Items in Dadun are protected by copyright, with all rights reserved, unless otherwise indicated.